Industry, CME, and OIG

WHILE THE OFFICE OF INSPECTOR General draft Compliance Program Guidance for Pharmaceutical Manufacturers, as published in early October, is directed specifically to the pharmaceutical industry, CME providers should take notice of several of its components. The Guidance addresses business policies and practices that could be in violation of federal statutes pertaining to kickbacks and false claims. In the mix is the possibility of fraud in industry-funded CME.